Kaohsiung Medical University
Kaohsiung Medical University was founded in 1954. It has been devoted to the cultivation of clinical and research talent in relevant medical, pharmaceutical, and bio-technological fields. KMU has 5 related Hospital. The biomedical service platform includes pharmaceutical trial, animal trial and clinical trial. Students graduated from the University are engaged in important works both domestically and internationally in the field of public medical care and contribute greatly to Taiwan's medical development. To work with medical industry closely, KMU establish Office for Operation of Industry and University Cooperation as one-stop service.
Kaohsiung Medical University| Alzheimer's Disease Assessment System
Solution Description
The association of Alzheimer's Disease International (ADI) estimates that there are more than 500 million people with dementia worldwide in 2019. By 2050, it is expected that the number of people with dementia will grow up to 100 million. Dementia-related costs currently stand at $1 trillion a year and are expected to double by 2030. AD accounts around 60 % of these demented patients, and it can not be cured currently. Given to heterogeneously therapeutic outcomes and no cured medicines for AD, there is no available makers to reflect clinical outcomes and provide adequate managements with referring to clinical big data. Different stage of AD has its needs. If we can predict the next stage for a AD patient, we can have appropriate managements to benefit patients and their caregivers. For above sakes, we have computed and integrated several clinical data pools to provide a predictive tool for AD outcomes.